Protagonist Logo. Click to navigate to a home page

INVESTOR RELATIONS

ANALYST COVERAGE

FIRM ANALYST
BTIG Julian Harrison
H.C. Wainwright Douglas Tsao, MPH
Jefferies Roger Song, MD, CFA
JMP Securities Jonathan Wolleben
J.P. Morgan Brian Cheng
Capital One Timothy Chiang

Protagonist Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Protagonist Therapeutics, Inc.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Protagonist Therapeutics, Inc. or its management. Protagonist Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.